Utilidad del 99mTc en la evaluación de remanentes tiroideos post tiroidectomía total


  1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0.
  2. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16:109-42.
  3. Brown RL. Standard and emerging therapeutic approaches for thyroid malignancies. Semin Oncol 2008; 35:298-308.
  4. Kloos RT. Papillary thyroid cancer: medical management and follow-up. Curr Treat Options Oncol 2005; 6:323-38.
  5. Lees W, Mansberg R, Roberts J, et al. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185MBq 131I. Eur J Nucl Med Mol Imaging 2002; 29:1421-7.
  6. Muratet JP, Daver A, Minier JF, et al. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated for differentiated thyroid carcinoma. J Nucl Med 1998; 39:1546-50.
  7. Vieras F. Preoperative scintigraphic detection of cervical metastases from thyroid carcinoma with technetium-99m pertechnetate. Clin Nucl Med 1985; 10:567-9.
  8. Khammash NF, Halkar RK, Abdel-Dayem HM. The use of technetium-99m pertechnetate in postoperative thyroid carcinoma. A comparative study with iodine-131. Clin Nucl Med 1988; 13:17-22.
  9. Kueh SS, Roach PJ, Schembri GP. Role of Tc-99m pertechnetate for remnant scintigraphy post thyroidectomy. Clin Nucl Med 2010; 35:671-4.
  10. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiate thyroid cancer. Thyroid 2009; 19:1167-214.
  11. Sawka AM, Thephamongkhol K, Brouwers M, et al. A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89:3668-76.
  12. Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 2008; 37:457-80.
  13. Kim S, Wei JP, Braveman JM, et al. Predicting outcome and directing therapy for papillary thyroid carcinoma. Arch Surg 2004; 139:390-4.
  14. Sanders LE, Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 1998; 133:419-25.
  15. Rodriguez E, Merlano S, Murguieitio R, et al. Terapia ablativa con yodo-131: juicio crítico de la evidencia. ¿Tiempo de cambiar paradigmas? Alasbimn Journal. Editorial, 20 octubre 2012.
  16. Schlumberger M, Catargi B, Borget I, et al. Strategies in radioiodine ablation in patients with low-risk thyroid cancer. N Eng J Med 2012; 366:1663-73.
  17. Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Eng J Med 2012; 366:1674-85.
  18. Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007; 246:375-81.
  19. Sywak M, Cornford L, Roach P, et al. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery 2006; 140:1000-7.
  20. Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 1998; 2:242-6.
  21. Hilditch TE, Dempsey MF, Bolster AA, et al. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Eur J Nucl Med Mol Imaging 2002; 29:783-8.
  22. Giovanella L, Suriano S, Ricci R, et al. Postsurgical thyroid remnant estimation by 99mTc pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma. Head Neck 2011; 33:552-6.